Biosilicified oncolytic adenovirus for cancer viral gene therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biosilicified oncolytic adenovirus for cancer viral gene therapy

Published:2020 Issue:19 Volume:8 Page:5317-5328
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Kong Hao¹²³⁴⁵^ORCID,Zhao Ruibo¹²³⁴⁵,Zhang Quan¹²³⁴⁵,Iqbal Muhammed Zubair¹²³⁴⁵,Lu Jiaju¹²³⁴⁵,Zhao Qingwei⁶⁷⁸⁹⁴,Luo Dandan¹²³⁴⁵,Feng Cui¹²³⁴⁵,Zhang Kangjian¹⁰¹¹¹²¹³¹⁴,Liu Xinyuan¹⁰¹¹¹²¹³¹⁴,Kong Xiangdong¹²³⁴⁵^ORCID

Affiliation:

1. School of Materials Science and Engineering

2. Zhejiang Sci-Tech University

3. Hangzhou 310018

4. China

5. Zhejiang-Mauritius Joint Research Center for Biomaterials and Tissue Engineering

6. Research Center for Clinical Pharmacy & Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province

7. The First Affiliated Hospital

8. Zhejiang University School of Medicine

9. Hangzhou 310003

10. State Key Laboratory of Cell Biology

11. Institute of Biochemistry and Cell Biology

12. Shanghai Institutes for Biological Sciences

13. Chinese Academy of Sciences

14. Shanghai 200031

Abstract

Biosilicified oncolytic adenovirus (OAs) significantly improved OAs distribution and tumor inhibition in vivo.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

Department of Education of Zhejiang Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/BM/D0BM00681E

Reference40 articles.

1. Gene therapy returns to centre stage

2. Oncolytic viruses get a boost with first FDA-approval recommendation

3. Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

4. Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs

5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging delivery strategy for oncolytic virotherapy;Molecular Therapy: Oncology;2024-06

2. Artificial Biomimetic Mineralization of Viruses: More than Calcium;Advanced NanoBiomed Research;2023-12-03

3. Erythrocyte‐Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects;Advanced Science;2023-11-23

4. Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus;Journal of Translational Medicine;2023-10-03

5. Innate Immune Response to Viral Vectors in Gene Therapy;Viruses;2023-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3